Combinations for the treatment of immunoinflammatory disorders

Details Combinations for the treatment of immunoinflammatory disorders Combinations for the treatment of immunoinflammatory disorders

2007-08-07

2007-08-07

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S177000, C514S179000, C514S180000, C514S258100

Reexamination Certificate

active

10264991

ABSTRACT:
The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit immunoinflammation.

REFERENCES:
patent: 3934036 (1976-01-01), Irikura
patent: 4034087 (1977-07-01), Voorhees
patent: 4107306 (1978-08-01), Voorhees
patent: 4367217 (1983-01-01), Gruber et al.
patent: 4499093 (1985-02-01), Galabov et al.
patent: 4554271 (1985-11-01), Braughler et al.
patent: 4685911 (1987-08-01), Konno et al.
patent: 4879119 (1989-11-01), Konno et al.
patent: 5242921 (1993-09-01), Milstone et al.
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5314688 (1994-05-01), Kauffman et al.
patent: 5326764 (1994-07-01), Milstone et al.
patent: 5428040 (1995-06-01), Magolda et al.
patent: 5468729 (1995-11-01), Chretien et al.
patent: 5639759 (1997-06-01), Magolda et al.
patent: 5668116 (1997-09-01), Cullis-Hill et al.
patent: 5756553 (1998-05-01), Iguchi et al.
patent: 5762918 (1998-06-01), Thorpe
patent: 5792476 (1998-08-01), Hallgren
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5874441 (1999-02-01), Magolda et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 6010716 (2000-01-01), Saunal et al.
patent: 6015577 (2000-01-01), Eisert et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6110910 (2000-08-01), Magolda et al.
patent: 6133272 (2000-10-01), Garvey et al.
patent: 6172060 (2001-01-01), Garvey et al.
patent: 6172068 (2001-01-01), Garvey et al.
patent: 6177428 (2001-01-01), Garvey et al.
patent: 6197778 (2001-03-01), Garvey et al.
patent: 6197782 (2001-03-01), Garvey et al.
patent: 6211179 (2001-04-01), Garvey et al.
patent: 6221881 (2001-04-01), Garvey et al.
patent: 6232321 (2001-05-01), Garvey et al.
patent: 6265427 (2001-07-01), Camden
patent: 6316457 (2001-11-01), Kapaan et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6337325 (2002-01-01), Schonharting et al.
patent: 6372254 (2002-04-01), Ting et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6403571 (2002-06-01), Gould et al.
patent: 6462044 (2002-10-01), Garvey et al.
patent: 6602521 (2003-08-01), Ting et al.
patent: 6677326 (2004-01-01), Bardsley et al.
patent: 6730321 (2004-05-01), Ting et al.
patent: 2001/0007083 (2001-07-01), Roorda et al.
patent: 2001/0016604 (2001-08-01), Yu et al.
patent: 2002/0019405 (2002-02-01), Garvey et al.
patent: 2003/0003151 (2003-01-01), Chopra
patent: 2003/0023087 (2003-01-01), Garvey et al.
patent: 2003/0069169 (2003-04-01), Macor et al.
patent: 2003/0077229 (2003-04-01), Dugger, III
patent: 2003/0203028 (2003-10-01), Ting et al.
patent: 2004/0087486 (2004-05-01), Hanson
patent: 2004/0087591 (2004-05-01), Garvey et al.
patent: 2004/0180812 (2004-09-01), Dicker et al.
patent: 2005/0025713 (2005-02-01), Dugger, III
patent: 2005/0058688 (2005-03-01), Boerger et al.
patent: 1246335 (2000-03-01), None
patent: 0 303 713 (1988-08-01), None
patent: 0 543 653 (1992-11-01), None
patent: 1093814 (2001-04-01), None
patent: 2 292 079 (1996-02-01), None
patent: WO 92/16226 (1992-01-01), None
patent: WO 92/16226 (1992-10-01), None
patent: WO 98/19672 (1998-05-01), None
patent: WO 98/55142 (1998-12-01), None
patent: WO 99/16417 (1999-04-01), None
patent: WO 99/62537 (1999-12-01), None
patent: WO 00/12076 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/59475 (2000-10-01), None
patent: WO 01/47572 (2001-07-01), None
patent: WO 01/54679 (2001-08-01), None
patent: WO 01/68056 (2001-09-01), None
patent: WO 02/085304 (2002-10-01), None
patent: WO 02/094227 (2002-11-01), None
patent: WO 03/043603 (2003-05-01), None
patent: WO 2004/019909 (2004-03-01), None
patent: WO 2004/069254 (2004-08-01), None
patent: WO 2005/020933 (2005-03-01), None
Berkow et al “Merck Manual of Medical Information,” Home edition, 1997, pp. 248-255.
Berkow et al. The Merck Manual, fifteen edition, 1987, pp. 797-807.
Sadamoto et al. ‘Thrombotic thrombocytopenic purpura in a patient with diffuse form of systemic sclerosis,’ Japanese Journal of Rheumatology, 1999, vol. 9, No. 3, pp. 267-272.
Barlow et al., “Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)”Bioorganic&Medicinal Chemistry Letters10:585-589 (2000).
Cass et al., “A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin)”Cancer Research52:5879-5886 (1992).
Cazenave et al., “Inhibition of platelet adherence to a collagen-coated surface by nonsteroidal anti-inflammatory drugs, pyrimido-pyrimidine and tricyclic compounds, and lidocaine”J. Lab. Clin. Med.83:797-806 (1974).
Curtin et al., “Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding”British Journal of Cancer80:1738-1746 (1999).
Goh et al., “Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues”Anticancer Research15:2575-2580 (1995).
Harada et al., “Renal amyloidosis associated with crescentic glomerulonephritis”Am. J. Nephrol.4:52-55 (1984).
Konstantinov et al., “Interferon response to dipyridamole in lupus erythematosus patients”British Journal of Dermatology121:59-63 (1989).
Lau et al., “Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole”Arthritis&Rheumatism38:248-253 (1995).
Lehman and Danenberg, “Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy”Cancer Chemother. Pharmacol.45:142-148 (2000).
Maezawa et al., “Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis”Clinical Nephrology42:30-32 (1994).
Vraux et al., “Inhibition of human monocyte TNF production by adenosine receptor agonsits”Life Sciences52:1917-1924 (1993).
Ziemnicka-Merchant et al., “Effects of chemical modification of nitrobenzyl thioinosine on its binding to high-affinity membrane binding sites and inhibition of nucleoside transport”Biochemical Pharmacology44:1577-1583 (1992).
Brunette et al., “Long-term Immunosuppressive Treatment of a Child with Takayasu's Arteritis and High IgE Immunoglobulins,” Pediatr. Nephrol. 10:67-69 (1996).
Bruserud, “Dipyridamol Inhibits Activation of Human T Lymphocytes In Vitro,” Clin. Immunol. Immunopathol. 42:102-109 (1987).
Eigler et al., “Endogenous Adenosine Curtails Lipopolysaccharide-Stimulated Tumour Necrosis Factor Synthesis,” Scan J. Immunol. 45:132-139 (1997).
Haskó et al., “Adenosine Inhibits IL-12 and TNF-α Production Via Adenosine A2aReceptor-Dependent and Independent Mechanisms,” FASEB J. 14:2065-2074 (2000).
Iijima et al., “Multiple Combined Therapy for Severe Henoch-Schönlein Nephritis in Children,” Pediatr. Nephrol. 12:244-248 (1998).
Nenci et al., “Effects of Dipyridamole on the Hypoxemic Pulmonary Hypertension of Patients with Chronic Obstructive Pulmonary Disease,” Respiration 53:13-19 (1988).
Rossi et al., “Thrombotic Thrombocytopenic Purpura,” JAMA 228:1141-1143 (1974).
Takeda et al., “Long-Term Corticosteroid and Dipyridamole Treatment of Membranoproliferative Glomerulonephritis Type I in Children,” Jpn J Nephrol 37:330-335 (1995).
Wagner et al., “Adenosine Inhibits Lipopolysaccharide-Induced Cardiac Expression of Tumor Necrosis Factor-α,” Circ. Res. 82:47-56 (1998).
Yoshikawa et al., “Combined Therapy with Prednisolon

Affiliated with

Also associated with

Rating

Combinations for the treatment of immunoinflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combinations for the treatment of immunoinflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations for the treatment of immunoinflammatory disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3893144